Accueil > Actualité
Actualite financiere : Actualite bourse

Pfizer: phase 3 endpoint achieved in haemophilia

( - Pfizer announced on Tuesday that its investigational drug marstacimab had met its primary endpoints in a phase 3 clinical trial for the treatment of severe A or B haemophilia.

The global study showed that the human monoclonal immunoglobulin reduced bleeding episodes by 92% in 116 patients followed for one year.

This is the third phase 3 program that is currently being conducted by Pfizer in severe haemophilia A or B, in addition to the gene therapies fidanacogene elaparvovec and giroctocogene fitelparvovec.

Copyright (c) 2023 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.